Wright Medical said it will appeal the FDA’s decision not to approve the Augment bone graft as an alternative to autograft in hind foot and ankle fusion procedures. The “not approvable” letter cited agency concerns that the Augment clinical trial population was “predominantly low-risk and therefore may not have warranted the use of either autograft or Augment Bone Graft,” Wright said.
MRI Study Shows Miach Orthopaedics BEAR Implant Restores Torn ACL Quality and Size Similar to Native ACLs
July 23, 2019
July 18, 2019
DJO® Announces Release of AltiVate Reverse® Short Stem, The First Fully Convertible, Inlay, Short Stem Shoulder Replacement System in the United States
July 16, 2019